Russia’s Nanolek eyes acceleration of expansion in vaccines segment

Russian drugmaker Nanolek plans to accelerate its expansion this year by expanding its range and increase of output, paying a particular focus to vaccines, The Pharma Letter’s local correspondent reports.

Vladimir Nesterenko, head of Nanolek said in an interview with the Russian Kommersant business paper, as part of the company’s plans it is developing its own vaccine production on full cycle basis, including the creation of a cell bank.

It is expected implementation of these plans will be carried through the deepening of cooperation with some major foreign partners of the company, such as French pharma major Sanofi (Euronext: SAN).